An interventional study of Vagus Nerve Stimulation (VNS) and Best Medical Treatment in Treatment Resistant Depression (TRD), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 24 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Depressive Disorder, Treatment-Resistant with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Depressive Disorder, Treatment-Resistant · France.
Among the 23 studies in Depressive Disorder, Treatment-Resistant with a site in France, this one is the 8th largest by planned enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2024, is one of 14 with no phase, and was the 12th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →9 of the 23 studies in Depressive Disorder, Treatment-Resistant with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier St Anne · Sites in France
Ages 18+
Centre Hospitalier St Anne · Sites in France
Ages 18+
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–70
Hôpital le Vinatier · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 166 is above the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 119 across the 21 interventional studies, 60 across the 2 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 23 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 2 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies in Depressive Disorder, Treatment-Resistant with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05577247Assistance Publique - Hôpitaux de ParisBelief Updating in Treatment Resistant Depression | 2026-12-13 |
| NCT05661383Hôpital le VinatierOlfactory and Brain Stimulations in Treatment-resistant Depression | 2027-01-27 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Depressive Disorder, Treatment-Resistant with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide.
Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption.
Sometimes, TRD is part of a bipolar illness. In this case, the challenge is even bigger because antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients.
The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response.
The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing long-term recurrences, and therefore responding to the lack of effective maintenance treatment in TRD. In fact, the benefits of VNS gradually accumulate over 12-24 months, which makes it complementary to more incisive treatments like ECT. Finally, its efficacy-tolerance profile appears to be similar in uni and bipolar TRD, giving VNS a potentially unique place in the therapeutic arsenal in psychiatry.
The DepVNS hypothesis is that VNS is a medico-economically efficient therapeutic option to overcome the therapeutic impasse in which patients suffering from uni and bipolar DR currently find themselves due to the frequency of relapses under treatment.
The primary objective is to estimate, from a collective point of view, the incremental cost-utility ratio of VNS to treat patients suffering from RD.
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide. The term treatment-resistant depression (TRD) is used when two or more (and often many more) well conducted antidepressant treatments from different classes have failed to achieve remission.
Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption. According to the World Health Organization (WHO), depression will be the second cause of healthcare costs in the world by 2020. RD alone accounts for 30 to 40% of the annual cost of depression.
Sometimes, TRD is part of a bipolar illness, a psychiatric condition characterized by the alternation of depressive and maniac episodes that affects 4% of the population. In this case, the challenge is even bigger because (1) antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, (2) the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients. Bipolar RD currently accounts for 20% of all psychiatric spending.
The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated because of the frequency and the intensity of the memory disorders associated, the repetition of anesthesia and hospitalizations and its social stigma. Refusals and requests to stop ECT are therefore common even when it is effective, as these constraints are sometimes experienced as being unbearable in the long-term. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response.
The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing the long-term recurrences, and therefore responding to the lack of effective maintenance treatment in TRD. In fact, the benefits of VNS gradually accumulate over 12-24 months, which makes it complementary to more incisive treatments like ECT. Finally, its efficacy-tolerance profile appears to be similar in uni and bipolar TRD, giving VNS a potentially unique place in the therapeutic arsenal in psychiatry. VNS has been approved for over 15 years as a treatment for RD in the Unites States and Great-Britain.
The hypothesis is that VNS is a medico-economically efficient therapeutic option to overcome the therapeutic impasse in which patients suffering from uni and bipolar DR currently find themselves due to the frequency of relapses under treatment.
The primary objective is to estimate, from a collective point of view, the incremental cost-utility ratio of VNS to treat patients suffering from RD.
The secondary objectives are evaluating the efficacy and the security of the VNS, as well as positioning the VNS in comparison with ECT that is currently the standard treatment for TRD.
This is a national multicenter comparative, open, randomized, controlled, two-parallel group clinical trial evaluating the medico-economic impact of VNS in resistant depression population. Patients (166) suffering from resistant depression will be enrolled over a 24-month period and will be randomized in a (1:1) ratio to receive either Vagus Nerve Stimulation (VNS) along with the Best Medical Treatment (VNS+BMT arm) or the Optimal Medical Treatment only (BMT arm).
Patients meeting all eligibility criteria will be enrolled in the study.
All subjects will be followed by the investigators or designee of the investigator during the whole study period by visits on site.
Number of visits/participant: Both arms will attend: selection visit (VS), inclusion visit (VI) and randomization visit (R), M0, M2, M4, M6, M8, M10, M12, M14, M16, M18, M20, M22 and M24. After the inclusion visit, the experimental arm (VNS + BMT) will further attend a neurosurgical and anesthetic consultation before being hospitalized for the VNS system placement. The patient will finally be hospitalized in psychiatry for about 5 days for switching the device on. If the target intensity has not been reached during this hospitalization, an adjustment visit is planned every month for 6 months in order to progressively increase the stimulation intensity until the target or a therapeutic response. If the target or the therapeutic response is obtained, the settings adjustments rhythm will be at the indiscretion of the psychiatrist. If at the end of the 6 first visits (M1 to M6), the target intensity couldn't be reached or in absence of a satisfying clinical response, a visit will be planned every 3 months (consultation or hospitalization) to keep optimizing the VNS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least one of the following criteria:
Exclusion Criteria:
Secondary Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Along with the Optimal Medical Treatment for resistant depression, the VNS + BMT arm will be implanted a medical device of VNS.
Device: Vagus Nerve Stimulation (VNS)
The BMT arm will only receive the Optimal Medical Treatment for resistant depression.
Other: Best Medical Treatment
The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.
Best Medical Treatment for resistant depression.
Cost-utility of VNS
Incremental cost-utility ratio of the Vagus Nerve Stimulation (group VNS + optimal medical treatment) in comparison to the control group (optimal medical treatment only) within 24 months of VNS placement
Time frame: Month 24
Efficacy of the VNS
Response rate (\< 50% amelioration of the QIDS-SR baseline score) cumulative and non-cumulative
Time frame: Month 24
Efficacy of the VNS
Remission rate (QIDS-SR score ≤ 5) cumulative and non cumulative
Time frame: Month 24
Efficacy of the VNS
CGI (Clinical Global Impression). Three scores: severity of the disease noted out of 7, overall improvement noted out of 7 and therapeutic index noted out of 16.
Time frame: Month 24
Efficacy of the VNS
EGF (Functioning Global Evaluation scale). Minimum: 0. Maximum: 100. The higher the score, the higher the level of psychological, social and occupational functioning.
Time frame: Month 24
Efficacy of the VNS
Number of weeks in depression, remission, (hypo)mania and number of major depressive episodes and (hypo)maniac episodes (DSM-5 criteria)
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of anxious symptoms : STAI-A (State-Trait Anxiety Inventory - Form A). Minimum: 20. Maximum: 80. A higher score indicates greater anxiety.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of thymus symptoms : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of thymus symptoms : YMRS (Young Mania Rating Scale). Minimum: 0. Maximum: 60. The higher the score, the more severe the symptoms.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of thymus symptoms : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of thymus symptoms : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of depressive episodes : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of depressive episodes : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of depressive episodes : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average duration of response periods (\< 50% improvement in QIDS-SR baseline score).
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of symptoms during the response phases : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of symptoms during the response phases : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of symptoms during the response phases : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of (hypo)maniac episodes: YMRS (Young Mania Rating Scale). Minimum: 0. Maximum: 60. The higher the score, the more severe the symptoms.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of (hypo)manic episodes: VAS mood (Visual Analogue Scale Mood ). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average intensity of (hypo)manic episodes: VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average duration of depressive episodes (DSM-5 criteria) and (hypo)manic episodes
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Interval between the major depressive episodes and interval between the (hypo)maniac episodes (DSM-5 criteria)
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Number of treatments/month
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Total cost of cares
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Quality of life : Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire Short Form). Score out of 70 and percentage. The higher the score, the higher the quality of life.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Quality of life : SF-36 (Short Form 36 Health Survey). 8 dimensions each evaluated out of 100. The higher the score, the higher the quality of life.
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Response rate (\< 50% improvement in QIDS-C baseline score) cumulative and non-cumulative
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Efficacy of the VNS
Average C-SSRS scoring
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Impact of the VNS on ECT (electroconvulsive therapy)
Cumulative number of ECT session within 24 months
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Impact of the VNS on ECT (electroconvulsive therapy)
Number of maintenance ECT session within 24 months
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Impact of the VNS on ECT (electroconvulsive therapy)
Average duration to obtain a complete ECT withdrawal
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Impact of the VNS on ECT (electroconvulsive therapy)
Average time period between ECT during the maintenance phase
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Impact of the VNS on ECT (electroconvulsive therapy)
Proportion of patients withdraw from ECT
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Impact of the VNS on ECT (electroconvulsive therapy)
Number of treatments per year
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Impact of the VNS on ECT (electroconvulsive therapy)
Results of EVA memory disorders severity
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Impact of the VNS on ECT (electroconvulsive therapy)
Montreal Cognitive Assessment (MoCA) scoring
Time frame: Months: 0, 12, 24
Security of the VNS
1/ VNS failure rate with a subgroup analysis for patients concomitantly treated by ECT, 2/Reported serious and non-serious adverse events
Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No — Datas are own by Assistance Publique - Hôpitaux de Paris, please contact sponsor for further information.
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Feb 2031, 84 months after the start.
Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 84 months is above that.
Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →
Assistance Publique - Hôpitaux de Paris →